A detailed history of Alpha Centric Advisors LLC transactions in Verona Pharma PLC stock. As of the latest transaction made, Alpha Centric Advisors LLC holds 50,000 shares of VRNA stock, worth $1.78 Million. This represents 1.22% of its overall portfolio holdings.

Number of Shares
50,000
Previous 56,000 10.71%
Holding current value
$1.78 Million
Previous $809,000 77.75%
% of portfolio
1.22%
Previous 0.67%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

SELL
$15.46 - $30.16 $92,760 - $180,960
-6,000 Reduced 10.71%
50,000 $1.44 Million
Q3 2023

Nov 13, 2023

BUY
$16.3 - $22.09 $16,300 - $22,090
1,000 Added 1.82%
56,000 $912,000
Q4 2022

Feb 07, 2023

BUY
$9.84 - $26.13 $147,600 - $391,950
15,000 Added 37.5%
55,000 $1.44 Million
Q3 2022

Nov 08, 2022

BUY
$4.14 - $13.59 $165,600 - $543,600
40,000 New
40,000 $409,000

Others Institutions Holding VRNA

About Verona Pharma plc


  • Ticker VRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,954,200
  • Market Cap $2.17B
  • Description
  • Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...
More about VRNA
Track This Portfolio

Track Alpha Centric Advisors LLC Portfolio

Follow Alpha Centric Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Centric Advisors LLC with notifications on news.